[{"id":"09a0d183-0830-4536-98ee-15af8f5f5f0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474025","created_at":"2026-03-28T01:40:03.290Z","updated_at":"2026-03-28T01:40:03.290Z","phase":"","brief_title":"Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses","source_id_and_acronym":"NCT07474025","lead_sponsor":"Jules Bordet Institute","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2026-03-16"},{"id":"a334d333-a3ba-49e5-a0c5-4e85464ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470489","created_at":"2026-03-28T01:44:21.005Z","updated_at":"2026-03-28T01:44:21.005Z","phase":"Phase 2","brief_title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","source_id_and_acronym":"NCT07470489","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/30/2026","start_date":" 09/30/2026","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2026-03-13"},{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"c31fe31a-3823-4e8c-81cc-892c70bccfed","acronym":"","url":"https://clinicaltrials.gov/study/NCT07206849","created_at":"2025-10-11T01:31:02.610Z","updated_at":"2025-10-11T01:31:02.610Z","phase":"Phase 2","brief_title":"Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)","source_id_and_acronym":"NCT07206849","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2025-10-03"},{"id":"78368562-545f-4c40-b6de-f2d2cbfd2a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT07183865","created_at":"2025-09-27T08:40:54.392Z","updated_at":"2025-09-27T08:40:54.392Z","phase":"Phase 2","brief_title":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","source_id_and_acronym":"NCT07183865","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/09/2025","start_date":" 03/09/2025","primary_txt":" Primary completion: 03/09/2030","primary_completion_date":" 03/09/2030","study_txt":" Completion: 03/09/2030","study_completion_date":" 03/09/2030","last_update_posted":"2025-09-19"},{"id":"da5af055-0246-4668-a44a-63ea071d356a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07158710","created_at":"2025-09-13T08:45:39.340Z","updated_at":"2025-09-13T08:45:39.340Z","phase":"Phase 1","brief_title":"Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation","source_id_and_acronym":"NCT07158710","lead_sponsor":"Haisco Pharmaceutical Group Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 05/23/2029","primary_completion_date":" 05/23/2029","study_txt":" Completion: 12/03/2029","study_completion_date":" 12/03/2029","last_update_posted":"2025-09-08"},{"id":"55b1a0de-6575-4213-92f4-3ad23c6cc089","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150403","created_at":"2025-09-06T13:44:19.461Z","updated_at":"2025-09-06T13:44:19.461Z","phase":"Phase 2","brief_title":"A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150403","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-09-02"},{"id":"5896371c-1ef5-48dc-96cb-56888e31ddde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150247","created_at":"2025-09-06T13:44:15.174Z","updated_at":"2025-09-06T13:44:15.174Z","phase":"Phase 2","brief_title":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150247","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-09-02"},{"id":"b0935c07-a451-47fa-8f96-112ab5dc4cae","acronym":"TATC","url":"https://clinicaltrials.gov/study/NCT07138261","created_at":"2025-08-30T14:02:24.019Z","updated_at":"2025-08-30T14:02:24.019Z","phase":"","brief_title":"Taiwanese Anaplastic Thyroid Cancer Registry","source_id_and_acronym":"NCT07138261 - TATC","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/30/2035","primary_completion_date":" 12/30/2035","study_txt":" Completion: 12/30/2035","study_completion_date":" 12/30/2035","last_update_posted":"2025-08-22"},{"id":"769c2f13-1a5f-40f3-a679-550e492e7f3c","acronym":"NeoART-M","url":"https://clinicaltrials.gov/study/NCT07095309","created_at":"2025-08-02T14:02:03.314Z","updated_at":"2025-08-02T14:02:03.314Z","phase":"Phase 2","brief_title":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","source_id_and_acronym":"NCT07095309 - NeoART-M","lead_sponsor":"Metanoic Health Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 08/30/2032","primary_completion_date":" 08/30/2032","study_txt":" Completion: 07/31/2033","study_completion_date":" 07/31/2033","last_update_posted":"2025-07-31"},{"id":"415c095a-fdbb-4c01-9393-539ef53dc7d9","acronym":"SuRage-EB","url":"https://clinicaltrials.gov/study/NCT07092410","created_at":"2025-08-02T14:07:29.999Z","updated_at":"2025-08-02T14:07:29.999Z","phase":"Phase 4","brief_title":"Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib","source_id_and_acronym":"NCT07092410 - SuRage-EB","lead_sponsor":"SRH Wald-Klinikum Gera GmbH","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 101","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 08/01/2030","primary_completion_date":" 08/01/2030","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-07-29"},{"id":"dd30cd49-1fd8-43e7-b783-449eccebfd62","acronym":"","url":"https://clinicaltrials.gov/study/NCT07070713","created_at":"2025-07-19T14:10:13.961Z","updated_at":"2025-07-19T14:10:13.961Z","phase":"Phase 2","brief_title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","source_id_and_acronym":"NCT07070713","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/30/2025","start_date":" 07/30/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 08/30/2028","study_completion_date":" 08/30/2028","last_update_posted":"2025-07-17"},{"id":"2006a2aa-ecdd-452a-aec0-f278d895e6f1","acronym":"OTELLO","url":"https://clinicaltrials.gov/study/NCT07064369","created_at":"2025-07-19T14:09:59.980Z","updated_at":"2025-07-19T14:09:59.980Z","phase":"","brief_title":"Observational Study on Thyroid Tumors and EvaLuation of the roLe of New pOntential Predictive/Prognostic Factors","source_id_and_acronym":"NCT07064369 - OTELLO","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 100","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-07-14"},{"id":"e87af69a-d323-4381-8103-c49ab9c91458","acronym":"","url":"https://clinicaltrials.gov/study/NCT06934538","created_at":"2025-07-12T13:49:40.870Z","updated_at":"2025-07-12T13:49:40.870Z","phase":"Phase 1/2","brief_title":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06934538","lead_sponsor":"Brenus Pharma","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • cyclophosphamide • oxaliplatin • STC-1010"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/17/2025","start_date":" 06/17/2025","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-07-11"},{"id":"5d7c4997-a66f-432c-ad34-60966069c8bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07054229","created_at":"2025-07-12T13:57:43.569Z","updated_at":"2025-07-12T13:57:43.569Z","phase":"","brief_title":"Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study","source_id_and_acronym":"NCT07054229","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 480","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-07-08"},{"id":"e43e3d0d-a928-4113-b0cb-1cb1cbe5fa52","acronym":"","url":"https://clinicaltrials.gov/study/NCT07044908","created_at":"2025-07-05T14:01:51.038Z","updated_at":"2025-07-05T14:01:51.038Z","phase":"Phase 1/2","brief_title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","source_id_and_acronym":"NCT07044908","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-07-01"},{"id":"cef8e42f-da33-450a-942c-ff0f7c445fa9","acronym":"PlugIN","url":"https://clinicaltrials.gov/study/NCT06906822","created_at":"2025-06-28T13:38:14.863Z","updated_at":"2025-06-28T13:38:14.863Z","phase":"Phase 2","brief_title":"PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients","source_id_and_acronym":"NCT06906822 - PlugIN","lead_sponsor":"Grupo Español Multidisciplinar de Melanoma","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-06-27"},{"id":"1b1049ad-72e3-482d-a433-13cd63e6b89e","acronym":"UK-EnBiRiM","url":"https://clinicaltrials.gov/study/NCT07022457","created_at":"2025-06-21T13:21:55.578Z","updated_at":"2025-06-21T13:21:55.578Z","phase":"","brief_title":"UK ENcorafenib and BInimetinib Real-world Study in Melanoma","source_id_and_acronym":"NCT07022457 - UK-EnBiRiM","lead_sponsor":"Vitaccess Ltd","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/23/2025","start_date":" 06/23/2025","primary_txt":" Primary completion: 12/06/2027","primary_completion_date":" 12/06/2027","study_txt":" Completion: 12/06/2027","study_completion_date":" 12/06/2027","last_update_posted":"2025-06-15"},{"id":"27333119-b7fd-424a-9cb7-3d186e837736","acronym":"","url":"https://clinicaltrials.gov/study/NCT06965114","created_at":"2025-06-14T13:57:06.110Z","updated_at":"2025-06-14T13:57:06.110Z","phase":"Phase 1/2","brief_title":"Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment","source_id_and_acronym":"NCT06965114","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-11"},{"id":"08660c39-94ce-46e6-891f-cb32c681d233","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012954","created_at":"2025-06-14T13:57:24.505Z","updated_at":"2025-06-14T13:57:24.505Z","phase":"Phase 1/2","brief_title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","source_id_and_acronym":"NCT07012954","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-06-10"},{"id":"5c7995c8-ead0-4dee-b97d-b534e2ba82a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07007689","created_at":"2025-06-07T14:23:15.486Z","updated_at":"2025-06-07T14:23:15.486Z","phase":"","brief_title":"A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer","source_id_and_acronym":"NCT07007689","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-06-06"},{"id":"3ba5c955-8ec9-4668-a6f6-e10f2a3b745e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07004075","created_at":"2025-06-07T14:43:33.080Z","updated_at":"2025-06-07T14:43:33.080Z","phase":"Phase 3","brief_title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","source_id_and_acronym":"NCT07004075","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • Ivesa (firmonertinib) • Fu Mai Ning (luvometinib) • vindesine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-06-04"},{"id":"ba38e7d6-cf30-459e-86ad-9dab62c47dd9","acronym":"FIRE-11","url":"https://clinicaltrials.gov/study/NCT07004413","created_at":"2025-06-07T14:43:38.689Z","updated_at":"2025-06-07T14:43:38.689Z","phase":"Phase 3","brief_title":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","source_id_and_acronym":"NCT07004413 - FIRE-11","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" BRAF • CA 19-9","pipe":"","alterations":" ","tags":["BRAF • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2025-06-04"},{"id":"f19011bc-a0f1-46bf-8979-e38379c2fbd2","acronym":"NEO-COMBATXL","url":"https://clinicaltrials.gov/study/NCT06902376","created_at":"2025-06-07T14:40:06.805Z","updated_at":"2025-06-07T14:40:06.805Z","phase":"Phase 1","brief_title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","source_id_and_acronym":"NCT06902376 - NEO-COMBATXL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/03/2025","start_date":" 06/03/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-06-04"}]